



# Tumor Microenvironment in Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis

Zhuangyu Guo, Xue Wang, \*Shuaishuai Huang, \*Guobin Weng

Urology Department, Ningbo Yinzhou No. 2 Hospital, Ningbo, Zhejiang Province, China

\*Corresponding Authors: Emails: ss.huang@aliyun.com, ddwgbin@aliyun.com

(Received 10 Jan 2024; accepted 27 Apr 2024)

## Abstract

**Background:** m6A RNA methylation and the tumor microenvironment (TME) have been reported to play important roles in the progression and prognosis of clear cell renal cell carcinoma (ccRCC). However, whether m6A RNA methylation regulators affect the TME in ccRCC remains unknown. Thus, we aimed to evaluate comprehensively the effect of m6A RNA methylation regulators on the TME in ccRCC.

**Methods:** Transcriptome data of ccRCC were obtained from TCGA database. Consensus clustering analysis was conducted based on the expression of m6A RNA methylation regulators. Survival differences were evaluated by Kaplan–Meier analysis between the clusters. The DESeq2 package was used to analyze the differentially expressed genes (DEGs) between the clusters. GO and KEGG pathway analyses were performed by the ClusterProfiler R package. The CIBERSORT algorithm was used to evaluate immune infiltration.

**Results:** The expression of 15 m6A regulators significantly differed between ccRCC and normal kidney tissues. Based on the expression of these 15 m6A regulators, two clusters were identified by consensus clustering, in which cluster 1 had better overall survival (OS). Overall, 4,429 DEGs were identified between the two clusters and were enriched in immune-related biological processes. Cluster 1 had lower immune and ESTIMATE scores, higher expression of HLA and lower expression of immune checkpoint molecules. Moreover, immune infiltration and expressions of Th1/IFN $\gamma$  gene signature were also significantly different between the two clusters.

**Conclusion:** Our study revealed m6A regulators were important participants in the development of ccRCC, with a close relationship with the TME.

**Keywords:** m6A RNA methylation regulator; Tumor microenvironment; Clear cell renal cell carcinoma

## Introduction

Renal cell carcinoma (RCC) ranks sixth in males and tenth in females among the most common cancers (1). Clear cell renal cell carcinoma (ccRCC), which accounts for 70%–80% of all RCCs, is the most frequent primary RCC (2). In recent years, the treatment of RCC has made

great progress with the development of surgical resection, chemotherapy and radiotherapy. However, overall survival (OS) is still dismal (3). One-third of patients relapse after an average of 1.9 yr (4), and patients who have local or distant metastasis further experience high mortality (5). Unfor-



Copyright © 2024 Guo et al. Published by Tehran University of Medical Sciences.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license.

(<https://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited

tunately, effective RCC prognostic markers are still lacking due to the high heterogeneity and complex disease process. Therefore, it is of great significance to analyze the pathogenesis at the molecular level and to predict accurately the prognosis of ccRCC patients.

N6-methyladenosine (m6A) has gained renewed interest as a new layer of gene expression regulation, participates in more than 60% of RNA methylation and has become the most common posttranscriptional modification of mRNA (6-8). The regulation of m6A exists in a reversible dynamic equilibrium (9). M6A can be produced by m6A methyltransferases (“writers”) and removed by m6A demethylases (“erasers”). Additionally, m6A-binding proteins (“readers”), including the YT521-B homology (YTH) domain family, insulin-like growth Factor 2 mRNA-binding proteins (IGF2BPs), and heterogeneous nuclear ribonucleoproteins (HNRNPs), are responsible for the identification of m6A-modified targeted RNAs (10). M6A RNA methylation regulators are involved in tumorigenesis and have a great impact on the survival of patients with various cancers, including ccRCC (11-14).

Cancer progression is inevitably related to an abnormal tumor microenvironment (TME). Deterioration of the TME promotes cancer cell escape from immune surveillance and accelerates the occurrence, development and metastasis of RCC (15). In addition, the interactions of chemokines with their receptors can recruit immune cell subsets into the TME to further modulate tumor progression and metastasis (16,17).

Abnormal m6A regulators are associated with the TME and immunotherapy responses in melanoma (18), colorectal cancer (19), gastric cancer (20) and head and neck squamous cell carcinoma (21), however, the interaction of m6A regulators with the microenvironment in ccRCC remains unclear. Thus, the purpose of this study was to evaluate comprehensively the correlation of m6A RNA methylation regulators with prognosis, immune checkpoint molecules, and the TME in ccRCC to better understand the etiology and provide new insight for immunotherapy of ccRCC.

## Methods

### *Identification of m6A RNA methylation regulators*

Twenty-one m6A regulators were identified in previous study (22). By using R package TCGA-biolinks, RNA-sequencing data and fragments per kilobase of exon model per million mapped fragments (FPKM) were downloaded from the TCGA database (<https://portal.gdc.cancer.gov/>), including mRNA expression data from 539 ccRCC and 72 normal samples. Next, the ensemble ID was converted to gene symbol by downloading the annotation file from GENCODE (<https://www.gencodegenes.org/human/>), extracting the mapping information of Gene Symbol and ENSG\_ID and finally mapping ENSG\_ID to Gene Symbol. The expression levels of m6A regulators were then obtained using R package Limma.

### *Consensus clustering analysis*

We used unsupervised consensus clustering analysis to classify ccRCC patients into different groups with distinct m6A modification patterns based on the overall expressions of m6A regulators that had significantly different expressions between ccRCC and normal kidney samples. Consensus clustering performed by “Consensus-ClusterPlus” R package is a reliable unsupervised machine learning method, in which we repeated 1000 repetitions by subsampling 80% of sample size and divided each subsample using k-means into multiple groups. The optimal number of clusters were determined by consensus matrix plot and cumulative distribution function (CDF) plot. The difference in OS between different clusters was assessed by the Kaplan–Meier method and log-rank test.

### *GO and KEGG pathway enrichment analysis of DEGs*

The DEGs between different clusters were identified using the DESeq2 package of R. A  $P < 0.05$  and  $|\log_2(\text{Fold change})| > 1$  were used to judge the statistical significance of gene expression dif-

ferences. The “ClusterProfiler R package” was used to analyze the GO and KEGG pathway enrichment. The GO terms included biological process, cellular component and molecular function. An adjusted  $P < 0.05$  was considered statistically significant.

#### *Evaluation of tumor microenvironment*

The immune score and ESTIMATE score were calculated by the ESTIMATE algorithm using the “ESTIMATE” R package. CIBERSORT was used to predict the proportion of 22 types of tumor infiltrating immune cells (memory B cells, naive B cells, activated dendritic cells, resting dendritic cells, eosinophils, M0 macrophages, M1 macrophages, M2 macrophages, activated mast cells, resting mast cells, monocytes, neutrophils, activated NK cells, resting NK cells, plasma cells, activated CD4<sup>+</sup> memory T cells, resting CD4<sup>+</sup> memory T cells, CD4<sup>+</sup> naive T cells, CD8<sup>+</sup> T cells, follicular helper T cells, gamma delta T cells, regulatory T cells) in each sample.

#### *Estimation of immunotherapeutic response*

The TIDE algorithm and subclass mapping were used to analyze the difference in response to PD-1 and CTLA-4 blockade between different clusters.

#### *Statistical analysis*


All data were analyzed by R (version 4.0.0), the Mann-Whitney-Wilcoxon test was used to com-

pare the data from different clusters, and a  $P < 0.05$  was considered statistically significant.

## **Results**

### *The expression of m6A regulators is related to the development of ccRCC*

We selected 21 m6A regulators for further investigation. As shown in Fig. 1A-B, the expression of 15 m6A regulators was significantly different between ccRCC and normal kidney tissues, among which the expression levels of *METTL3*, *WTAP*, *RBM15*, *FTO*, *ALKBH5*, *YTHDC2* and *IGF2BP3* were higher in ccRCC samples than in normal samples. Compared with ccRCC samples, the expression of *METTL14*, *ZC3H13*, *RBM15B*, *YTHDF2*, *YTHDF3*, *IGF2BP2*, *HNRNPC* and *HNRNPA2B1* was significantly increased in normal kidney samples. The results of Kaplan–Meier analysis showed that 9 m6A regulators, including *METTL3*, *WTAP*, *YTHDC2*, *IGF2BP3*, *METTL14*, *ZC3H13*, *YTHDF3*, *IGF2BP2*, and *HNRNPA2B1*, were associated with the prognosis of ccRCC patients. ccRCC patients with higher expression of *METTL3*, *IGF2BP3*, *WTAP*, *IGF2BP2* and *HNRNPA2B1* had a more favorable prognosis, while patients with higher expression of *METTL14*, *ZC3H13*, *YTHDF3* and *YTHDC2* had a shorter survival time (Fig. 1C). These results indicated that the expression of m6A regulators was related to the development of ccRCC.




**Fig. 1:** Expression of m6A methylation regulators and OS analysis in ccRCC patients. Heatmap (A) and Violin plot (B) visualizing the expression levels of m6A methylation regulators among ccRCC and normal kidney tissues. Survival analyses for m6A methylation regulators with high or low expression by the Kaplan–Meier method (C)

**Identification of two subtypes in ccRCC based on the expression of m6A regulators**

Consensus clustering was then performed to classify ccRCC patients into clusters based on the expression of these 15 m6A regulators. Notably, K=2 was identified with optimal clustering (Fig. 2A-B). A total of 479 ccRCC patients were clus-

tered into two subgroups, with 337 patients in cluster 1 and 142 patients in cluster 2. In addition, the PCA results clearly showed that there were two distinct distributions of the two clusters (Fig. 2C). Kaplan–Meier analysis showed that the patients of cluster 1 had a better OS than those of cluster 2 (Fig. 2D).




**Fig. 2:** Identification of two subgroups in ccRCC based on m6A regulator levels. (A) CDF visualization for k equals 2 to 6; (B) Consensus clustering matrix for k equals 2; PCA (C) and Kaplan–Meier (D) analysis of the two clusters

### *Biological function analysis of DEGs between cluster 1 and cluster 2*

To better characterize the difference in biological processes involved in the development of ccRCC between the two clusters, we compared the expression of genes in the two clusters, and 4,429 DEGs were found (Fig. 3A). To obtain further insights into the biological characteristics of the DEGs, GO and KEGG pathway analyses were performed. GO analysis showed that the DEGs were enriched in immune-related functions, such as regulation of immune effector process, production of molecular mediator of immune re-

sponse, immune response-activating cell surface receptor signaling pathway, lymphocyte mediated immunity, B cell mediated immunity, immunoglobulin mediated immune response and regulation of humoral immune response (Fig. 3B). Moreover, the results of the KEGG pathway analysis revealed several immune-related pathways, such as cytokine-cytokine receptor interaction, calcium signaling pathway, complement and coagulation cascades and bile secretion (Fig. 3C). These results demonstrated that m6A regulators were involved in the immunity of ccRCC patients.




**Fig. 3:** Biological functional annotation of DEGs among the two clusters. Volcano map (A), GO (B) and KEGG (C) analyses of 4,429 DEGs

**Identification of different TME characteristics between cluster 1 and cluster 2**

We studied the TME characteristics of the two clusters to explore further the role of m6A regulators in ccRCC. The expression patterns of m6A regulators and TME features in cluster 1 and cluster 2 are shown by the heatmap (Fig. 4A). Specifically, the immune and ESTIMATE scores

were remarkably higher in cluster 2 ( $P=0.0027$  and  $P=0.018$ , respectively), and the stromal score of cluster 2 was relatively higher with no statistical significance compared to cluster 1 ( $P=0.8$ ) (Fig. 4B-D), suggesting that m6A regulators were correlated with immune infiltration and tumor purity.




**Fig. 4:** Identification of different TME characteristics between the two clusters. (A) Heatmap visualizing m6A regulators and TME features between the two clusters. Comparison of the immune (B), ESTIMATE (C) and stromal (D) scores between cluster 1 and cluster 2

**Identification of different immune landscapes between cluster 1 and cluster 2**

Given the significant difference in the TME between the two clusters, we performed CIBERSORT analysis to estimate the immune infiltration of the two clusters. The distribution of immune cells was compared between cluster 1 and cluster 2 (Fig. 5) (Supplementary Fig. 1- not published). The abundances of 11 immune cell types were significantly different between the two clus-

ters, with higher proportions of naive B cells, CD4<sup>+</sup> naive T cells, regulatory T cells, activated CD4<sup>+</sup> memory T cells and M0 macrophages and lower proportions of plasma cells, M1 macrophages, resting NK cells, monocytes, resting rest cells and neutrophils in cluster 2. Clustering subgroups based on the expression of m6A regulators were closely related to the immune microenvironment in ccRCC.




**Fig. 5:** Evaluation of immune cell infiltration between the two clusters. (A) The immune infiltration in each sample. (B) Comparison of 22 kinds of immune cells between the two clusters

*Identification of different expression levels of HLA, immune checkpoint molecules and Th1/IFN $\gamma$  pathway signatures between cluster 1 and cluster 2*

We found that the expression of 12 HLA genes significantly differed between the two clusters, among which the expression of 11 HLA genes ( $P < 0.05$ ) (Fig. 6A). The 19 immune checkpoint molecules were remarkably differentially ex-

pressed between the two clusters, of which cluster 2 had higher expression of 17 immune checkpoints ( $P < 0.05$ ) (Fig. 6B). For the genes involved in the Th1/IFN $\gamma$  pathway, the expression of IFNGR2, IFN $\gamma$  and STAT1 was upregulated in cluster 2 ( $P < 0.05$ ), whereas the expression of JAK1 and JAK2 was upregulated in cluster 1 ( $P < 0.05$ ) (Fig. 6C). m6A regulators may affect the

immune response and TME by regulating the expression of HLA, immune checkpoint molecules and Th1/IFN $\gamma$  pathway gene signatures. As shown in Fig. 6D, cluster 2 presented a very poor response to anti-CTLA-4 therapy (Bonferroni corrected  $P = 0.048$ ). These results indicated that m6A regulators had a close relationship with therapeutic efficacy.



**Fig. 6:** The influence of m6A regulators on the immunotherapeutic response of ccRCC patients. Comparisons of HLAs (A), immune checkpoint levels (B) and the Th1/IFN $\gamma$  pathway (C) between cluster 1 and cluster 2. Comparison of response to PD1 and CTLA4 immunotherapies (D). PD1-R means patients respond to PD1 treatment. PD1-noR means patients do not respond to PD1 treatment. In the vertical axis, p means nominal  $P$  value, and b means Bonferroni corrected  $P$  value

## Discussion

Increasing evidence has demonstrated that m6A modification plays an indispensable role in inflammation, innate immunity and antitumor ef-

fects through interaction with different m6A regulators. Cancer research studies have shown that m6A regulator-mediated methylation is involved in tumorigenesis and angiogenesis, and this occurs partially through alteration of the TME.

However, the effect of m6A RNA methylation regulators on the TME of ccRCC remained unclear. In the current study, ccRCC patients could be divided into two clusters with distinct expression patterns of m6A regulators. Further bioinformatics revealed that patients in two clusters had significantly different overall survival, tumor microenvironment (immune infiltration, expressions of immune checkpoints, enrichment of immune-related pathways) and immunotherapeutic response, indicating that the interaction between m6A modification and tumor microenvironment is of great significance in the prognosis and treatment of ccRCC patients.

First, we compared the expression of 21 m6A regulators between ccRCC and normal kidney tissues and found that 15 m6A regulators had remarkably different expression levels, of which the expression abundance between ccRCC and normal kidney tissues was consistent with previous reports (11, 23). Among these dysregulated m6A regulators, we noticed that patients with higher expression of METTL3, IGF2BP3, WTAP, IGF2BP2 and HNRNPA2B1 had a better prognosis, whereas patients with higher expression of METTL14, ZC3H13, YTHDF3 and YTHDC2 had a worse prognosis (Fig. 1C). Writers were regarded as the main m6A regulators and were related to patient OS in ccRCC (24). Our present study also confirmed the vital roles of the writers METTL3, METTL14, WTAP and ZC3H13 in predicting ccRCC patient OS. As members of the “reader” regulators, we observed that YTHDC2 and YTHDF3 were negatively correlated with ccRCC patient OS, while IGF2BP2, IGF2BP3 and HNRNPA2B1 were positively correlated, and these findings were similar to previous reports (25-28). Additionally, in other studies, erasers of FTO (Niu et al in breast cancer (29)) and ALKBH5 (Chen et al in hepatocellular carcinoma (30)) and readers of YTHDF2 (Li et al in Osteosarcoma (28), Zhang et al in lung adenocarcinoma (31)) and HNRNPC (Huang et al in gastric cancer (32)), Zhao et al in head and neck squamous cell carcinoma (33)) have been reported to be related to the OS of patients; however, in the current study, we found

that these regulators exhibited no significant relationships with OS in ccRCC. Therefore, we speculated that the contributions of these m6A regulators to OS differed in distinct cancers, which may be due to different tumorigenesis mechanisms. More reliable experiments are needed to clarify this phenomenon.

Based on the expression of these 15 m6A methylation regulators, consensus clustering was applied to classify ccRCC patients into two subgroups, cluster 1 and cluster 2 (Fig. 2A). We found that cluster 1 had better OS than cluster 2 (Fig. 2D). Furthermore, when comparing the expression profiles of the two clusters, we found 4429 DEGs with different expression levels. Both GO and KEGG pathway enrichment analyses suggested that the DEGs participated in immune-related biological processes and signaling (Fig. 3B and C), which indicated that m6A regulators might be associated with immunity. The TME is closely associated with the immune response in ccRCC progression (17). Therefore, we next compared the TME and its related indicators (immune cell infiltration, HLA, immune checkpoint and Th1/IFN $\gamma$  pathway gene expression), reported to be closely associated with immunity (34, 35), between the two clusters. Interestingly, we found that TME and its related indicators did differ between the two clusters, including abundance of stromal cells, immune cell infiltrates, expressions of HLAs and other checkpoint molecules, enrichment of immune-related pathways and immunotherapeutic responses.

In the current study, cluster 2, with shorter OS, had higher immune, stromal and ESTIMATE scores. Our results were consistent with the study of Xu et al (36), who divided their glioma samples into two subgroups and found that clusters with higher stroma ( $P < 0.05$ ), immune ( $P < 0.05$ ), and ESTIMATE scores ( $P < 0.05$ ) were associated with shorter OS. However, Liu et al found that patients with higher immune scores were significantly positively associated with OS time in endometrial carcinoma (37). The conflicting results may be caused by the diverse immune microenvironment and tumorigenesis mechanisms of different tumors.

According to our results, low HLA levels in ccRCC contributed to the inactivation of cytotoxic immune mechanisms, which in turn led to a worse OS in cluster 2 than in cluster 1. High-grade immune infiltration is usually accomplished with low levels of HLA-I-positive cancer cells. Based on our results, lower HLA-I levels in cluster 2 may contribute to higher immune scores (immune cell infiltration level of tumor tissue) than those in cluster 1.

Both the TME and immune checkpoints are associated with the therapeutic response (38). In the present study, we compared the expression of immune checkpoint molecules, the activation of which enables tumor cells to evade immune suppression and found that cluster 2 had relatively higher expression of immune checkpoints. Crucial immune checkpoints were mostly positively correlated with “CD8<sup>+</sup> T cells”, “activated memory CD4<sup>+</sup> T cells” and “M1 macrophages” but negatively correlated with “resting memory CD4<sup>+</sup> T cells”, “M0 macrophages” and “activated dendritic cells” (37). Similarly, higher expression of immune checkpoints in cluster 2 was also accompanied by abundant activated memory CD4<sup>+</sup> T cells, M0 macrophages, and lower M1 macrophages. Additionally, due to the differences in immune checkpoint molecules, we inferred that the immunotherapeutic response of cluster 1 and cluster 2 might be different. Therefore, we compared the responses of the two clusters to two commonly used immunotherapies, PD-1 and CTLA-4. Both clusters had a poor response to these two treatments, and cluster 2 had no significant response to CTLA-4 therapy. M6A regulators may influence the effect of immunotherapy, at least PD-1 and CTLA-4 treatment, in ccRCC.

## Conclusion

M6A regulators are important participants in the development of ccRCC and are closely related to the TME. This study provides a new understanding of the role of m6A methylation in ccRCC and suggests that m6A regulators may affect the immune response and TME by regulating the ex-

pression of HLA, immune checkpoint molecules and Th1/IFN $\gamma$  pathway gene signatures.

## List of abbreviations

TME: Tumor microenvironment; ccRCC: Clear cell renal cell carcinoma; TCGA: The Cancer Genome Atlas; DEGs: Differentially expressed genes; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; HLA: Human leukocyte antigen; OS: Overall survival; m6A: N6-methyladenosine; RCC: Renal cell carcinoma; YTH: YT521-B homology.

## Availability of data and materials

Supplementary materials may be requested by respected readers from corresponding author.

## Journalism Ethics considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

## Acknowledgements

We are greatly appreciated the excellent assistance of Dr. Samsel Kelton from Ningbo University for revising the language carefully. This work was supported by General Health Foundation of Zhejiang Province (2021KY1067) and Zhejiang Key Laboratory of Pathophysiology (No.201910).

## Conflict of interest

The authors declare that there is no conflict of interests.

## References

1. Siegel RL, Miller KD, Jemal A (2018). Cancer statistics, 2018. *CA Cancer J Clin*, 68(1): 7-30.
2. Rini BI, Campbell SC, Escudier B (2009). Renal cell carcinoma. *Lancet*, 373(9669): 1119-32.

3. Greef B, Eisen T (2016). Medical treatment of renal cancer: new horizons. *Br J Cancer*, 115(5): 505-16.
4. Stewart SB, Thompson RH, Psutka SP, et al (2014). Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. *J Clin Oncol*, 32(36): 4059-65.
5. Caceres W, Cruz-Chacon A (2011). Renal cell carcinoma: molecularly targeted therapy. *P R Health Sci J*, 30(2): 73-7.
6. Wang S, Sun C, Li J, et al (2017). Roles of RNA methylation by means of N(6)-methyladenosine (m(6)A) in human cancers. *Cancer Lett*, 408: 112-120.
7. Du K, Zhang L, Lee T, Sun T (2019). m(6)A RNA Methylation Controls Neural Development and Is Involved in Human Diseases. *Mol Neurobiol*, 56(3): 1596-1606.
8. Chen M, Wong CM (2020). The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis. *Mol Cancer*, 19(1): 44.
9. Cao G, Li HB, Yin Z, Flavell RA (2016). Recent advances in dynamic m6A RNA modification. *Open Biol*, 6(4): 160003.
10. Qin Y, Li L, Luo E, et al (2020). Role of m6A RNA methylation in cardiovascular disease (Review). *Int J Mol Med*, 46(6): 1958-1972.
11. Chen J, Yu K, Zhong G, Shen W (2020). Identification of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of clear cell renal carcinoma. *Cancer Cell Int*, 20: 157.
12. Zhang QJ, Luan JC, Song LB, et al (2020). m6A RNA methylation regulators correlate with malignant progression and have potential predictive values in clear cell renal cell carcinoma. *Exp Cell Res*, 392(1): 112015.
13. Liu T, Li C, Jin L, Li C, Wang L (2019). The Prognostic Value of m6A RNA Methylation Regulators in Colon Adenocarcinoma. *Med Sci Monit*, 25: 9435-9445.
14. Chen M, Nie ZY, Wen XH, Gao YH, Cao H, Zhang SF (2019). m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer. *Biosci Rep*, 39(12): BSR20192892.
15. Lei X, Lei Y, Li JK, et al (2020). Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. *Cancer Lett*, 470: 126-133.
16. Lee YS, Cho YB (2020). CCL7 Signaling in the Tumor Microenvironment. *Adv Exp Med Biol*, 1231: 33-43.
17. Senbabaoglu Y, Gejman RS, Winer AG, et al (2016). Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. *Genome Biol*, 17(1): 231.
18. Wang L, Hui H, Agrawal K, et al (2020). m(6)A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. *EMBO J*, 39(20): e104514.
19. Li N, Kang Y, Wang L, et al (2020). ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. *Proc Natl Acad Sci U S A*, 117(33): 20159-20170.
20. Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL (2020). m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. *Mol Cancer*, 19(1): 53.
21. Zhou GQ, Lv JW, Tang LL, et al (2020). Evaluation of the National Comprehensive Cancer Network and European Society for Medical Oncology Nasopharyngeal Carcinoma Surveillance Guidelines. *Front Oncol*, 10: 119.
22. Xu Z, Chen Q, Shu L, Zhang C, Liu W, Wang P. (2022). Expression profiles of m6A RNA methylation regulators, PD-L1 and immune infiltrates in gastric cancer. *Front Oncol*, 12: 970367.
23. Zheng Z, Mao S, Guo Y, et al (2020). N6methyladenosine RNA methylation regulators participate in malignant progression and have prognostic value in clear cell renal cell carcinoma. *Oncol Rep*, 43(5): 1591-1605.
24. Gao W, Cheng L, He S, et al (2020). Multiomics integrative analysis for gene signatures and prognostic values of m(6)A regulators in pancreatic adenocarcinoma: a retrospective study in The Cancer Genome Atlas project. *Aging (Albany NY)*, 12(20): 20587-20610.
25. Zhou X, Han J, Zhen X, et al (2020). Analysis of

- Genetic Alteration Signatures and Prognostic Values of m6A Regulatory Genes in Head and Neck Squamous Cell Carcinoma. *Front Oncol*, 10: 718.
26. Liu L, Liu X, Dong Z, et al (2019). N6-methyladenosine-related Genomic Targets are Altered in Breast Cancer Tissue and Associated with Poor Survival. *J Cancer*, 10(22): 5447-5459.
  27. Cui XH, Hu SY, Zhu CF, Qin XH (2020). Expression and prognostic analyses of the insulin-like growth factor 2 mRNA binding protein family in human pancreatic cancer. *BMC Cancer*, 20(1): 1160.
  28. Li J, Rao B, Yang J, et al (2020). Dysregulated m6A-Related Regulators Are Associated With Tumor Metastasis and Poor Prognosis in Osteosarcoma. *Front Oncol*, 10: 769.
  29. Niu Y, Lin Z, Wan A, et al (2019). RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. *Mol Cancer*, 18(1): 46.
  30. Chen Y, Zhao Y, Chen J, et al (2020). ALKBH5 suppresses malignancy of hepatocellular carcinoma via m(6)A-guided epigenetic inhibition of LYPD1. *Mol Cancer*, 19(1): 123.
  31. Zhang Y, Liu X, Liu L, Li J, Hu Q, Sun R (2020). Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma. *Med Sci Monit*, 26: e919644.
  32. Huang H, Han Y, Zhang C, et al (2016). HNRNPC as a candidate biomarker for chemoresistance in gastric cancer. *Tumour Biol*, 37(3): 3527-34.
  33. Zhao X, Cui L (2019). Development and validation of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of head and neck squamous cell carcinoma. *Am J Cancer Res*, 9(10): 2156-2169.
  34. Pitt JM, Vetizou M, Daillere R, et al (2016). Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. *Immunity*, 44(6): 1255-69.
  35. Popovic A, Jaffee EM, Zaidi N (2018). Emerging strategies for combination checkpoint modulators in cancer immunotherapy. *J Clin Invest*, 128(8): 3209-3218.
  36. Xu S, Tang L, Dai G, Luo C, Liu Z (2020). Expression of m6A Regulators Correlated With Immune Microenvironment Predicts Therapeutic Efficacy and Prognosis in Gliomas. *Front Cell Dev Biol*, 8: 594112.
  37. Liu J, Nie S, Wu Z, et al (2020). Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial carcinoma microenvironment. *Genomics*, 112(5): 3117-3134.
  38. Chon HJ, Lee WS, Yang H, et al (2019). Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. *Clin Cancer Res*, 25(5): 1612-1623.